Tsaur I, Heidegger I, Bektic J, et al. - It was shown that abiraterone acetate (AA)+androgen deprivation therapy (ADT) is mainly correlated with similar efficacy and overall toxicity rate as docetaxel (D)+ADT. There is a need for a further prospective study to confirm the clinical value of the observed benefit of AA+ADT for progression-free end-points.

• Researchers designed a retrospective multicenter analysis including a total of 196 patients.

• The results showed that the AA+ADT cohort had a longer PFS1 in the log-rank testing (23 vs. 13 mos., p < 0.001), a longer progression-free survival 2 (PFS2) (48 vs. 33 mos., p = 0.006), and longer overall survival (OS) (80 vs. 61 mos., p = 0.040).

• Although OS and toxicity rate were similar between both groups, in the multivariate analyses AA+ADT outperformed D+ADT in terms of PFS1 (HR = 0.34, 95% CI = 0.183–0.623; p = 0.001) and PFS2 (HR = 0.33 95% CI = 0.128–0.827; p = 0.018), respectively.